{"id":"NCT00678535","sponsor":"Merck KGaA, Darmstadt, Germany","briefTitle":"Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer","officialTitle":"Open-label, Randomized, Controlled, Multicenter Phase III Study Investigating Cetuximab in Combination With Capecitabine (Xeloda, X) and Cisplatin (P) Versus XP Alone as First-line Treatment for Subjects With Advanced Gastric Adenocarcinoma Including Adenocarcinoma of the Gastroesophageal Junction","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-06","primaryCompletion":"2012-03","completion":"2013-02","firstPosted":"2008-05-15","resultsPosted":"2013-05-16","lastUpdate":"2014-07-21"},"enrollment":904,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Gastric Cancer"],"interventions":[{"type":"DRUG","name":"Cetuximab","otherNames":["Erbitux"]},{"type":"DRUG","name":"Capecitabine","otherNames":["Xeloda"]},{"type":"DRUG","name":"Cisplatin","otherNames":[]}],"arms":[{"label":"Cetuximab plus Capecitabine plus Cisplatin","type":"EXPERIMENTAL"},{"label":"Capecitabine plus Cisplatin","type":"ACTIVE_COMPARATOR"}],"summary":"The primary objective of this study is to demonstrate that addition of cetuximab to 1st-line treatment with capecitabine (Xeloda, X) and cisplatin (P) \\[XP\\] chemotherapy regimen has a clinically relevant benefit for subjects with advanced gastric adenocarcinoma including gastroesophageal junction (GEJ) adenocarcinoma, in terms of progression free survival (PFS).\n\nSecondary objectives are to assess cetuximab plus XP versus XP alone with respect to overall survival, overall tumor response, quality of life (QoL) and safety.","primaryOutcome":{"measure":"Progression-free Survival (PFS) Time: Independent Review Committee (IRC) Assessments","timeFrame":"Time from randomization to disease progression, death or last tumor assessment, reported between day of first participant randomized, that is, 30 Jun 2008 until cut-off date (31 Mar 2012)","effectByArm":[{"arm":"Cetuximab Plus Capecitabine Plus Cisplatin","deltaMin":4.4,"sd":null},{"arm":"Capecitabine Plus Cisplatin","deltaMin":5.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.3158"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":16,"exclusionCount":16},"locations":{"siteCount":130,"countries":["Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Chile","China","Czechia","France","Germany","Greece","Hong Kong","Hungary","Israel","Italy","Japan","Poland","Portugal","Romania","Russia","South Korea","Spain","Taiwan","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":239,"n":446},"commonTop":["Nausea","Neutropenia","Decreased appetite","Vomiting","Fatigue"]}}